Where they can cause debilitating diseases such as inflammatory bowel disease.

Possible new therapies for IBD by learning how you could increase the antibacterial functions of of this particular group of cells are developed, said Dr. Lora Hooper, associate professor of immunology and senior author of the study. The results could also help researchers to better understand how probiotics mixtures of beneficial bacteria boost the immune system boost the immune system to add .. Their latest knowledge available online today and in a future edition of the Proceedings of the National Academy of Sciences, suggest that a once enigmatic cell population which lurks in the intestinal lining is essential for the prevention of friendly bacteria from invading into deeper tissue, where they can cause debilitating diseases such as inflammatory bowel disease .

For this study the researchers examined mice genetically modified to a mysterious immune cell gamma called deltaintraepithelial lymphocytes lacking (IEL these specialized T cell to body surfaces such as the skin and? gastro-intestinal tract, where it has itself between the epithelial cells that form these surfaces available. These cells a large part of the body’s T cells, but their exact function was unclear. Our results suggest that an important function of these T cells in the intestinal borders, sensing when microorganisms patrol penetrated the epithelial cells of the intestine, Dr. Who is also an investigator for the Howard Hughes Medical Institute at UT Southwestern said. When this happens, these T cells action action, so that antibiotics proteins that kill the rogue bacteria and prevent entry into deeper tissue layers.Highlights of the meeting includes specific symposium, Educational, special interest seminars and scientific meeting.

IL – been licensed in Europe for rheumatoid arthritis.

Over Actemra / RoActemraRoACTEMRA is the result of the research collaboration by Chugai and globally with Chugai globally with Chugai RoACTEMRA is the first humanised IL-6 receptor monoclonal antibody as in Japan , Actemra was by Chugai in June 2005. Therapeutic for Castleman disease launched, registered April 2008, additional indications for RA, polyarticular juvenile idiopathic arthritis and systemic – onset juvenile idiopathic arthritis have been also Japan. Is expectedTEMRA is generally well tolerated. The overall safety profile by RoActemra being across all global clinical trial.

Published by